SternAegis Ventures

DarioHealth is a digital health company focused on developing and commercializing innovative technology for health management. It offers a mobile, real-time diabetes management solution through its Dario Blood Sugar Monitor, which combines a blood glucose monitoring device with a cloud-based software application. In addition to diabetes management, DarioHealth provides personalized, evidence-based interventions for various health conditions, including hypertension, weight management, musculoskeletal pain, and behavioral health. The company utilizes precision data analytics and personalized coaching to enhance user engagement and effectiveness. Operating internationally, DarioHealth generates revenue primarily from the sale of its Dario smart meter and related disposable test strip cartridges and lancets, positioning itself at the intersection of life sciences, behavioral science, and software technology.

Laconic Enterprises, LLC is a specialty firm based in Toronto, Canada, dedicated to infrastructure development in the energy sector. The company focuses on constructing and managing projects aimed at addressing critical energy availability challenges faced by governments and government-sponsored enterprises around the world. Through its expertise in high-value-add projects, Laconic Enterprises seeks to provide effective solutions to enhance energy access and reliability on a global scale.

Zoomcar is a leading peer-to-peer car-sharing marketplace based in Bengaluru, India, specializing in self-drive rentals and vehicle subscriptions. Founded in 2013, the company operates a technology-driven platform that features over 20,000 vehicles across India, Southeast Asia, and Egypt. By empowering host entrepreneurs to share their cars, Zoomcar allows them to earn passive income while providing guests with a diverse and affordable selection of vehicles. The company's primary revenue comes from short-term self-drive rentals, with India being its largest market. Zoomcar employs over 300 people and operates in 50 cities, including locations in Indonesia, Vietnam, and Egypt. Uri Levine, a notable entrepreneur known for his work with mobility companies, serves as the Chairman of the Board.

Super League Enterprise hosts recreational video game league events in movie theaters. It aims to give gamers an entirely new way to enjoy the games they love. The Santa Monica-based company cut its teeth producing Minecraft events nationwide, an event series that continues to grow. Never content thinking small, Super League Gaming goes big. Its competitions take place in state-of-the-art movie theaters. All the action is played out on big screens and bolstered with thundering sound systems. In partnership with Riot Games, Super League Gaming is now readying City Champs and City Rec League of Legends events which offer players new ways to compete, learn, socialize and have fun playing their favorite games in a local league.

Dance Biopharm Inc. is a biopharmaceutical company dedicated to developing inhaled insulin products for diabetes management. The company’s primary focus is on its lead candidate, Dance 501, which is currently undergoing Phase II clinical trials. This innovative product combines a pocket-sized inhaler device with an insulin container, allowing adults with diabetes to manage their prandial blood sugar levels without the need for traditional injections. Founded in 2009 and based in Brisbane, California, Dance Biopharm Inc. was previously known as Dance Pharmaceuticals, Inc. before rebranding in February 2013. Through its advancements in inhaled insulin therapies, the company aims to improve the treatment experience for diabetes patients worldwide.

Clover Inc. is a Toronto-based company that develops a mobile dating and chat application aimed at facilitating meaningful connections among online daters. Founded in 2014, the app allows users to discover potential matches based on location, preferences, and timing. It offers features that enable individuals to browse profiles of nearby users who have expressed interest, as well as find popular venues for dates. By simplifying the process of meeting new people, Clover enhances the dating experience, making it easier for users to connect and arrange meetups.

Amplifica is a preclinical stage biopharmaceutical company dedicated to developing innovative treatments for androgenic alopecia, commonly known as hair loss. The company employs a nature-inspired scientific approach, focusing on a molecular mechanism designed to promote the regrowth of natural hair. Amplifica has successfully identified and isolated unique signaling molecules that stimulate hair follicles, offering healthcare professionals effective solutions for treating hair loss.

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.

Psudo is a footwear company based in Saint Louis, Missouri, that specializes in manufacturing sustainable sneakers. Founded in 2021, the company utilizes locally sourced materials and eco-friendly recycled fabrics to create lightweight and affordable shoes. Psudo's sneakers are designed to provide antimicrobial properties and anatomically supportive features, ensuring comfort for all-day wear. Through its commitment to sustainability, Psudo aims to offer a diverse range of eco-conscious footwear options for consumers.

Outstanding Foods, Inc. is a plant-based food company that specializes in creating vegan snacks, primarily marketed under the PigOut Rinds and TakeOut Puffs brands. Founded in 2016 and headquartered in Venice, California, the company focuses on producing flavorful snacks using pure, wholesome ingredients and proprietary chef-crafted methods. Outstanding Foods aims to provide consumers with nutritious, high-protein options that contain no animal ingredients, allowing them to enjoy tasty snacks without guilt. The company was previously known as Fresh Soul Holdings, Inc. until it rebranded in March 2017.

Dance Biopharm Inc. is a biopharmaceutical company dedicated to developing inhaled insulin products for diabetes management. The company’s primary focus is on its lead candidate, Dance 501, which is currently undergoing Phase II clinical trials. This innovative product combines a pocket-sized inhaler device with an insulin container, allowing adults with diabetes to manage their prandial blood sugar levels without the need for traditional injections. Founded in 2009 and based in Brisbane, California, Dance Biopharm Inc. was previously known as Dance Pharmaceuticals, Inc. before rebranding in February 2013. Through its advancements in inhaled insulin therapies, the company aims to improve the treatment experience for diabetes patients worldwide.

DermaSensor, Inc. is a Miami-based company that develops a handheld device designed to evaluate skin lesions for cancer using artificial intelligence and spectroscopy. Founded in 2009, the company's flagship product enables both physicians and consumers to conduct skin checks conveniently in clinical settings and at home. The device employs elastic scattering spectroscopy and machine learning algorithms to rapidly assess skin lesions, helping to identify potential cancerous cells. By providing an affordable and efficient tool for early detection, DermaSensor aims to improve access to skin cancer evaluations, addressing the significant number of Americans who have never undergone such checks. The technology not only facilitates immediate assessments but also alerts users when cancerous cells are detected, streamlining the process of skin cancer diagnostics.

Viscient Biosciences is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in drug discovery and development, leveraging innovative human 3D tissue technology combined with multi-omics analysis, which includes genomics, transcriptomics, and metabolomics. This approach allows Viscient to identify genes and pathways that contribute to disease progression, with an initial focus on non-alcoholic steatohepatitis, commonly known as fatty liver disease. The team at Viscient comprises experienced scientists and entrepreneurs from Organovo and Ardea Biosciences, and they aim to transform the traditional drug discovery process, moving away from reliance on animal models to more effective human-based methodologies.

Zoomcar is a leading peer-to-peer car-sharing marketplace based in Bengaluru, India, specializing in self-drive rentals and vehicle subscriptions. Founded in 2013, the company operates a technology-driven platform that features over 20,000 vehicles across India, Southeast Asia, and Egypt. By empowering host entrepreneurs to share their cars, Zoomcar allows them to earn passive income while providing guests with a diverse and affordable selection of vehicles. The company's primary revenue comes from short-term self-drive rentals, with India being its largest market. Zoomcar employs over 300 people and operates in 50 cities, including locations in Indonesia, Vietnam, and Egypt. Uri Levine, a notable entrepreneur known for his work with mobility companies, serves as the Chairman of the Board.

Hydrobuilder.com offers a large selection of indoor grow lights, complete hydroponic system, plant nutrients, ventilation systems, grow tents and more! Hydrobuilder supplies both hobby and commercial cultivators in all 50 states.

Zoomcar is a leading peer-to-peer car-sharing marketplace based in Bengaluru, India, specializing in self-drive rentals and vehicle subscriptions. Founded in 2013, the company operates a technology-driven platform that features over 20,000 vehicles across India, Southeast Asia, and Egypt. By empowering host entrepreneurs to share their cars, Zoomcar allows them to earn passive income while providing guests with a diverse and affordable selection of vehicles. The company's primary revenue comes from short-term self-drive rentals, with India being its largest market. Zoomcar employs over 300 people and operates in 50 cities, including locations in Indonesia, Vietnam, and Egypt. Uri Levine, a notable entrepreneur known for his work with mobility companies, serves as the Chairman of the Board.

Outstanding Foods, Inc. is a plant-based food company that specializes in creating vegan snacks, primarily marketed under the PigOut Rinds and TakeOut Puffs brands. Founded in 2016 and headquartered in Venice, California, the company focuses on producing flavorful snacks using pure, wholesome ingredients and proprietary chef-crafted methods. Outstanding Foods aims to provide consumers with nutritious, high-protein options that contain no animal ingredients, allowing them to enjoy tasty snacks without guilt. The company was previously known as Fresh Soul Holdings, Inc. until it rebranded in March 2017.

DarioHealth is a digital health company focused on developing and commercializing innovative technology for health management. It offers a mobile, real-time diabetes management solution through its Dario Blood Sugar Monitor, which combines a blood glucose monitoring device with a cloud-based software application. In addition to diabetes management, DarioHealth provides personalized, evidence-based interventions for various health conditions, including hypertension, weight management, musculoskeletal pain, and behavioral health. The company utilizes precision data analytics and personalized coaching to enhance user engagement and effectiveness. Operating internationally, DarioHealth generates revenue primarily from the sale of its Dario smart meter and related disposable test strip cartridges and lancets, positioning itself at the intersection of life sciences, behavioral science, and software technology.

Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.

DermaSensor, Inc. is a Miami-based company that develops a handheld device designed to evaluate skin lesions for cancer using artificial intelligence and spectroscopy. Founded in 2009, the company's flagship product enables both physicians and consumers to conduct skin checks conveniently in clinical settings and at home. The device employs elastic scattering spectroscopy and machine learning algorithms to rapidly assess skin lesions, helping to identify potential cancerous cells. By providing an affordable and efficient tool for early detection, DermaSensor aims to improve access to skin cancer evaluations, addressing the significant number of Americans who have never undergone such checks. The technology not only facilitates immediate assessments but also alerts users when cancerous cells are detected, streamlining the process of skin cancer diagnostics.

Outstanding Foods, Inc. is a plant-based food company that specializes in creating vegan snacks, primarily marketed under the PigOut Rinds and TakeOut Puffs brands. Founded in 2016 and headquartered in Venice, California, the company focuses on producing flavorful snacks using pure, wholesome ingredients and proprietary chef-crafted methods. Outstanding Foods aims to provide consumers with nutritious, high-protein options that contain no animal ingredients, allowing them to enjoy tasty snacks without guilt. The company was previously known as Fresh Soul Holdings, Inc. until it rebranded in March 2017.

Dance Biopharm Inc. is a biopharmaceutical company dedicated to developing inhaled insulin products for diabetes management. The company’s primary focus is on its lead candidate, Dance 501, which is currently undergoing Phase II clinical trials. This innovative product combines a pocket-sized inhaler device with an insulin container, allowing adults with diabetes to manage their prandial blood sugar levels without the need for traditional injections. Founded in 2009 and based in Brisbane, California, Dance Biopharm Inc. was previously known as Dance Pharmaceuticals, Inc. before rebranding in February 2013. Through its advancements in inhaled insulin therapies, the company aims to improve the treatment experience for diabetes patients worldwide.

DarioHealth is a digital health company focused on developing and commercializing innovative technology for health management. It offers a mobile, real-time diabetes management solution through its Dario Blood Sugar Monitor, which combines a blood glucose monitoring device with a cloud-based software application. In addition to diabetes management, DarioHealth provides personalized, evidence-based interventions for various health conditions, including hypertension, weight management, musculoskeletal pain, and behavioral health. The company utilizes precision data analytics and personalized coaching to enhance user engagement and effectiveness. Operating internationally, DarioHealth generates revenue primarily from the sale of its Dario smart meter and related disposable test strip cartridges and lancets, positioning itself at the intersection of life sciences, behavioral science, and software technology.

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.

Hydrofarm is a leading distributor and manufacturer of controlled environment agriculture equipment and supplies, focusing on enhancing the productivity and efficiency of growers, farmers, and cultivators. With over 40 years of experience, the company offers a diverse range of products, including high-intensity grow lights, climate control solutions, premium soils, and nutrients, marketed under both proprietary and distributed brands. Hydrofarm operates primarily in the U.S. and Canadian markets, providing innovative solutions that support the needs of the agriculture community. By prioritizing quality and consistency, Hydrofarm aims to empower its customers in their growing endeavors.

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.

BackBeat Medical Inc. is a medical technology company established in 2010, focused on developing innovative cardiac stimulation therapies for conditions such as hypertension and heart failure. The company has created a patented treatment known as programmable hypertension control (PHC) therapy, which utilizes proprietary pacing algorithms that can be integrated into standard pacemakers. This approach allows for a broad application in treating patients with hypertension, particularly those who already have or require pacemakers. Clinical studies demonstrate that BackBeat's Moderato™ pacemaker, equipped with PHC algorithms, achieves significant reductions in blood pressure, with average decreases of 24 mmHg in office measurements and 14 mmHg in 24-hour ambulatory assessments. Follow-up data indicate sustained therapeutic effects over extended periods. BackBeat's PHC therapy is supported by a comprehensive global patent portfolio.

Dance Biopharm Inc. is a biopharmaceutical company dedicated to developing inhaled insulin products for diabetes management. The company’s primary focus is on its lead candidate, Dance 501, which is currently undergoing Phase II clinical trials. This innovative product combines a pocket-sized inhaler device with an insulin container, allowing adults with diabetes to manage their prandial blood sugar levels without the need for traditional injections. Founded in 2009 and based in Brisbane, California, Dance Biopharm Inc. was previously known as Dance Pharmaceuticals, Inc. before rebranding in February 2013. Through its advancements in inhaled insulin therapies, the company aims to improve the treatment experience for diabetes patients worldwide.

Adgero Biopharmaceuticals is a biopharmaceutical company focused on developing innovative photodynamic therapy (PDT) for the treatment of serious oncology indications, particularly rare and unmet medical needs in cancer. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero's lead product, REM-001 Therapy, utilizes a combination of laser light, a light delivery device, and a drug to target cutaneous metastatic cancers. The therapy has shown promising safety and efficacy results in Phase 2/3 clinical trials, specifically for patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. The company's ongoing research aims to leverage existing data and complete further clinical trials to facilitate potential regulatory approval for REM-001, thereby expanding treatment options for patients suffering from serious skin cancers.

Caliber Therapeutics, Inc. is focused on developing and commercializing minimally-invasive balloon-based drug delivery products aimed at treating atherosclerotic diseases. The company's primary offering is the Targeted Angioplasty Drug Delivery balloon, which serves as a stent-free platform for administering anti-restenotic drugs. This innovative approach facilitates controlled and targeted drug delivery, significantly reduces the risk of thrombosis, and diminishes the necessity for permanent device implantation. Headquartered in Monmouth Junction, New Jersey, Caliber Therapeutics is committed to enhancing patient outcomes and expediting treatment processes for vascular diseases.

Motus GI is a medical technology company that focuses on improving outcomes in endoscopy and enhancing patient experiences in the diagnosis and management of gastrointestinal conditions. Based in Fort Lauderdale, Florida, and with operations in Israel, the company has developed the Pure-Vu System, a medical device designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures. This device aims to facilitate better visualization and improve the overall effectiveness of the colonoscopy, contributing to the early detection and prevention of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and is also CE marked for use in the European Economic Area.

Helocyte Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative immunotherapies for the prevention and treatment of cytomegalovirus (CMV). A portfolio company of Fortress Biotech, Helocyte is advancing three key programs that originated from research at City of Hope in California. The first, PepVax, is a peptide vaccine designed to control CMV in patients who have undergone allogeneic hematopoietic stem cell transplantation. The second program, Triplex, is a universal recombinant viral vector vaccine that expresses three immuno-dominant proteins linked to CMV, also intended for use in allogeneic HSCT recipients and potentially in solid organ transplant patients. The third program, Pentamer, aims to prevent congenital CMV by targeting five primary subunits of the virus. Currently, Pentamer is in nonclinical development. Through these initiatives, Helocyte seeks to enhance patient outcomes in both cancer and infectious disease contexts.

Adgero Biopharmaceuticals is a biopharmaceutical company focused on developing innovative photodynamic therapy (PDT) for the treatment of serious oncology indications, particularly rare and unmet medical needs in cancer. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero's lead product, REM-001 Therapy, utilizes a combination of laser light, a light delivery device, and a drug to target cutaneous metastatic cancers. The therapy has shown promising safety and efficacy results in Phase 2/3 clinical trials, specifically for patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. The company's ongoing research aims to leverage existing data and complete further clinical trials to facilitate potential regulatory approval for REM-001, thereby expanding treatment options for patients suffering from serious skin cancers.

Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.

Dance Biopharm Inc. is a biopharmaceutical company dedicated to developing inhaled insulin products for diabetes management. The company’s primary focus is on its lead candidate, Dance 501, which is currently undergoing Phase II clinical trials. This innovative product combines a pocket-sized inhaler device with an insulin container, allowing adults with diabetes to manage their prandial blood sugar levels without the need for traditional injections. Founded in 2009 and based in Brisbane, California, Dance Biopharm Inc. was previously known as Dance Pharmaceuticals, Inc. before rebranding in February 2013. Through its advancements in inhaled insulin therapies, the company aims to improve the treatment experience for diabetes patients worldwide.

Corbus Pharmaceuticals is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, that focuses on developing and commercializing therapeutics for inflammatory and fibrotic diseases. Founded in 2009, the company’s lead product candidate, lenabasum, is a synthetic oral CB2 agonist currently undergoing Phase III clinical trials for systemic sclerosis and dermatomyositis, and Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition to lenabasum, Corbus is developing CRB-4001, a peripherally-restricted CB1 inverse agonist aimed at treating nonalcoholic steatohepatitis and other fibrotic conditions. The company is leveraging a diverse pipeline of drug candidates sourced from a library of over 600 novel compounds targeting the endocannabinoid system. Furthermore, Corbus has established collaborations for the development and commercialization of its products, including a partnership with Kaken Pharmaceutical Co., Ltd. for lenabasum in Japan.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia; and MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

DarioHealth is a digital health company focused on developing and commercializing innovative technology for health management. It offers a mobile, real-time diabetes management solution through its Dario Blood Sugar Monitor, which combines a blood glucose monitoring device with a cloud-based software application. In addition to diabetes management, DarioHealth provides personalized, evidence-based interventions for various health conditions, including hypertension, weight management, musculoskeletal pain, and behavioral health. The company utilizes precision data analytics and personalized coaching to enhance user engagement and effectiveness. Operating internationally, DarioHealth generates revenue primarily from the sale of its Dario smart meter and related disposable test strip cartridges and lancets, positioning itself at the intersection of life sciences, behavioral science, and software technology.

Armada Water Assets is a Houston-based company that specializes in water supply, collection, and remediation services. Established in 2012, it focuses on the safe and cost-effective management of contaminated water generated from conventional oil and gas production, as well as from hydraulic fracturing activities. The company provides a comprehensive range of services, including the collection, handling, transport, treatment, and reuse of produced water and flow-back water, ensuring that these processes meet environmental standards while supporting the energy industry's operational needs.

Deem, Inc. is a technology company specializing in Commerce-as-a-Service (CaaS) solutions tailored for the business travel industry. Founded in 1999 and headquartered in San Francisco, California, Deem offers a comprehensive cloud-based suite of applications that streamline travel, expense management, and purchasing for companies. Its platform empowers organizations to manage travel bookings for flights, hotels, and ground transportation while ensuring compliance with corporate spending policies. Additionally, Deem enables merchants to effectively promote and sell their products and services through various channels, enhancing customer engagement with options such as card-linked offers and corporate discounts. The company's focus is on simplifying business travel for employees, reducing costs for employers, and creating profitable opportunities for service providers. Deem operates as a subsidiary of Enterprise Holdings, Inc.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Organovo Holdings, Inc. is a biotechnology company based in Solana Beach, California, specializing in the development of bioprinted human tissues using its innovative 3D human tissue platform technology. This platform features proprietary NovoGen Bioprinters, which create living tissues from mammalian cells, along with technologies for bio-inks and complex multicellular structures. Organovo offers ExVive human liver and kidney tissues, which are utilized for predictive preclinical drug testing. Additionally, the company is working on in vivo liver tissues aimed at treating severe liver diseases and developing NovoTissues liver products using cells from both liver and umbilical cord donors. Founded in 2007, Organovo aims to address unmet medical needs through its advanced tissue engineering capabilities, contributing to the field of regenerative medicine.

InVivo Therapeutics is a medical device company dedicated to developing treatments aimed at restoring function in individuals suffering from spinal cord injuries. Founded in 2005, the company leverages polymer-based platform technology to create innovative solutions for both acute and chronic spinal cord injuries. Its product pipeline includes the Neuro spinal scaffold and bioengineered neural trails, reflecting its commitment to advancing the field of spinal cord repair. The company operates through a clinical development program focused on acute spinal cord injuries while also engaging in preclinical efforts for chronic cases. Based in Cambridge, Massachusetts, InVivo Therapeutics is at the forefront of research and clinical advancements in the treatment of spinal cord injuries.

PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.

Psudo is a footwear company based in Saint Louis, Missouri, that specializes in manufacturing sustainable sneakers. Founded in 2021, the company utilizes locally sourced materials and eco-friendly recycled fabrics to create lightweight and affordable shoes. Psudo's sneakers are designed to provide antimicrobial properties and anatomically supportive features, ensuring comfort for all-day wear. Through its commitment to sustainability, Psudo aims to offer a diverse range of eco-conscious footwear options for consumers.